Calixa: Bettering cephalosporin

Calixa Therapeutics Inc. is developing an in-licensed cephalosporin it says is more potent against multi-drug resistant strains of Pseudomonas aeruginosa than all other available beta lactams. The lead compound, CXA-101, and two follow-ons are in development for Gram-negative nosocomial infections.

Beta lactams, which include cephalosporins, carbapenems, penicillins and monobactams, are the most potent class of antibiotics against P. aeruginosaand are commonly used as first-line antibiotics for nosocomial infections...